Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans

Hypertension

Volumn 35, Issue 5, 2000, Pages 1148-1153

  Laurent, Stéphane ^a   Boutouyrie, Pierre ^a   Azizi, Michel ^a   Marie, Christine ^b   Gros, Claude ^c   Schwartz, Jean Charles ^c   Lecomte, Jeanne Marie ^d   Bralet, Jean ^b  

^a HÔPITAL BROUSSAIS   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c INSERM   (France)

^d Laboratoire Bioprojet   (France)

Author keywords

Angiotensin converting enzyme; Angiotensin converting enzyme inhibitors; Enzyme; Hypertension, essential; Neprilysin

Indexed keywords

CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; FASIDOTRIL; MEMBRANE METALLOENDOPEPTIDASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RENOVASCULAR HYPERTENSION; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0034110537     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.5.1148     Document Type: Article

References (35)

1. Schwartz JC, Gros C, Lecomte JM, Bralet J. Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci. 1990;47:1279-1287.
2. Sybertz EJ, Chiu PJS, Watkins RW, Vemulapalli S. Neutral metalloen-dopeptidase inhibition: a novel means of circulatory modulation. J Hypertens. 1990;8(suppl 7):S161-S167.
3. Smits JFM. Pharmacological intervention in the renin-angiotensin system in hypertension. In: Van Zwieten PA, Greenlee WJ, eds. Antihypertensive Drugs. Newark, NJ: Harwood Academic Publishers: 1997:377-408.
4. Hirata Y, Matsuoka H, Hayakawa H, Sugimoto T, Suzuki E, Sugimoto T, Kangawa K, Matsuo H. Role of endogenous atrial natriuretic peptide in regulating sodium excretion in spontaneously hypertensive rat: effect of neutral endopeptidasc inhibition. Hypertension. 1991;17:1025-1032.
5. Pham I, Gonzalez W, El Amrani AIK, Fournié-Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther. 1993;265: 1339-1347.
6. O'Connell JE, Jardine AG, Davidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992;10:271-277.
7. Singer DRJ, Markendu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension. 1991;18:798-804.
8. Kosoglou T, Herron JM, Chen R. Given B, Sybertz EJ, Affrime MB. Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation. 1990;82:(suppl 3):554. Abstract.
9. LeFrançois P, Clerc G, Duchier J, Lim C, Lecomte JM, Gros C, Schwartz JC. Antihypertensive activity of sinorphan. Lancet. 1990;336:307-308.
10. Richards AM, Crozier IG, Kosoglou T, Railings M, Espiner EA, Nicholls MG, Yandle TG, Ikram H, Frampton C. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension. 1993;22: 119-126.
11. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607-613.
12. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13: 797-804.
13. Robl JA, Trippodo NC, Petrillo EW. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin converting enzyme. In: Van Zwieten PA, Greenlee WJ, eds. Antihypertensive Drugs. Newark, NJ: Harwood Academic Publishers; 1997:113-212.
14. Gros C, Nöel N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, Duhamel L, Duhamel P, Lecomte JM, Bralet J. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci U S A. 1991;88: 4210-4214.
15. Giros B, Gros C, Schwartz JC, Dany D, Plaquevent JC, Duhamel L, Duhamel P, Vlaiculescu A, Costentin J, Lecomte JM. Enantiomers of thiorphan and acetorphan: correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effects. J Pharmacol Exp Ther. 1987;243:666-673.
16. Carmel A, Yaron A. An intramolecularly quenched fluorescent tripeptide as a fluorogenic substrate of angiotensin I-converting enzyme and of bacterial carboxypeptidase. Eur J Biochem. 1978;87:265-273.
17. Bralet J, Mane C, Mossiat C, Lecomte JM, Gros C, Schwartz JC. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction: comparison with captopril. J Pharmacol Exp Ther. 1994;270:8-14.
18. Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol. 1991;17:456-465.
19. Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci USA. 1994;91: 4072-4076.
20. Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995;275:745-752.
21. Webb RL, Abramson ML, Beil ME, Odorico LM, Chatelain R. Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1997;30:632-642.
22. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363-372.
23. Itoh H, Nakao K, Mukoyama M, Yamada T, Hosoda K, Shirakami G, Morii N, Sugawara A, Saito Y, Shiono S, Aral H, Yoshida I, Imura H. Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats. J Clin Invest. 1989;84:145-154.
24. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
25. Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther. 1998;64:439-449.
26. Richards AM, Wittert GA, Crozier IJ, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407-416.
27. Motwani JG, Lang CC, Cramb G, Struthers AD. Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension. 1995;25(pt 1):637-642.
28. MacFayden RJ, Lees KR, Reid JL. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol. 1991;31:1-13.
29. Waeber B, Brunner HB, Brunner DB, Curtet AL, Turini GA, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980;2:236-242.
30. Kurtz A, Della-Bruna R, Pfeilshister J, Taugner R. Bauer C. Atrial natriuretic peptide inhibits renin release from isolated renal juxtaglomerular cells by a c-GMP mediated process. Proc Natl Acad Sci USA. 1986;83:4769-4773.
31. Smith JB, Lincoln TM. Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor. Am J Physiol. 1987;253:C147-C150.
32. Bhoolla KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev. 1992;44:1-80.
33. Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 1998;287: 567-577.
34. Welches WR, Brosnihan KB, Ferrario MC. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin-converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 1993;52:1461-1480.
35. Norton GR, Woodiwiss AJ, Hartford C, Trifunovic B, Middlemost S, Lee A, Allen MJ. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999;12:563-571.